<DOC>
	<DOC>NCT00198445</DOC>
	<brief_summary>The primary objective of this study was to investigate the efficacy of bromfenac sodium ophthalmic solution 0.09% for treatment of post-operative ocular inflammation in subjects who undergo cataract extraction and intraocular lens implantation. The secondary objective was to investigate the safety and tolerability of the same.</brief_summary>
	<brief_title>Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Postoperative Complications</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Cataract surgery Summed ocular inflammation score (anterior chamber cell score plus flare score) of &gt;/= 3, 24 hours after the cataract extraction Agreed to avoid disallowed medications (meds) throughout the duration of the study Use of or need for nonsteroidal antiinflammatory agents (NSAIDs), steroids, anticoagulants, or other specific meds prohibited by the protocol Uncontrolled chronic ocular or systemic disease, active corneal pathology or scarring noted in either eye (except keratopathy, allowed in nonstudy eye) Extraocular/intraocular inflammation in either eye Clinically significant (WHO CTC Grade 1 or greater) liver function tests</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Cataract Extraction</keyword>
	<keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
</DOC>